Checkpoint inhibitor immunotherapy, consisting of anti-CTLA4 and anti-PD1, is effective in the treatment of a variety of cancers42–45, and the feasibility of using immunotherapy to treat pancreatic cancer will receive increasing attention and research. Here, CTLA4 is linked to pancreatic neoplasm.